Key result
Sirolimus-eluting stents showed a significantly higher frequency of uncovered struts compared to Paclitaxel-eluting stents at 9 months (12.5% vs 4.9%, P=0.01), although coverage was incomplete in both.
Why the study?
Does the use of sirolimus-eluting stents compared to paclitaxel-eluting stents affect neointimal coverage at 9 months after implantation?
Observational (n=60)
Blinded analysis
No
Does the use of sirolimus-eluting stents compared to paclitaxel-eluting stents affect neointimal coverage at 9 months after implantation?
Absolute Event Rate: 12.5% vs 4.9%
p-value: p=0.01
At 9 months post-implantation, sirolimus-eluting stents showed a higher frequency of uncovered struts compared to paclitaxel-eluting stents, though both had incomplete coverage.
No takes yet. Share an insight, caveat, or question.
Sirolimus-eluting stents were associated with more uncovered struts; hypothesis-generating for differential healing, should not yet change practice.
Kim et al. (2010) conducted an observational in Coronary artery disease (Acute coronary syndrome or stable angina pectoris) (n=60). Sirolimus-eluting stents vs. Paclitaxel-eluting stents was evaluated on Frequency of uncovered struts (p=0.01). Sirolimus-eluting stents showed a significantly higher frequency of uncovered struts compared to Paclitaxel-eluting stents at 9 months (12.5% vs 4.9%, P=0.01), although coverage was incomplete in both.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: